Prospective rAndomized, single-blind, mulTicenter control clinical study of sirolimus-eluting coRonary stent “Calypso” vs everolimus-elutIng cOronary stenT “Xience Prime”: design and rationale for “PATRIOT” trial


Full Text:

PDF (Russian)


Abstract


Aim. This study is aimed at evaluating the efficacy and safety of sirolimus-eluting coronary stent “Calypso” in comparison with everolimus-eluting coronary stent “Xience Prime” in patients with ischemic heart disease.
Methods. This is a prospective, randomized, single-blind multicenter clinical trial in patients undergoing coronary revascularization with coronary stenting. Seven clinical sites in Russia will enroll 610 patients with coronary artery disease. Patients suitable for coronary stenting will be randomized in group 1 (n=406) to receive coronary stent “Calypso” (“Angioline”, and group 2 (n=204) to receive coronary stent Xience Prime (Abbott). Clinical follow-up will continue for 1 year. By the end of follow-up, a quantitative coronary angiography will be performed in 122 patients (20 %).
Conclusion. A randomized trial “PATRIOT” is designed to prove the efficacy and safety of sirolimus-eluting coronary stent “Calypso” in comparison with everolimus-eluting coronary stent “Xience Prime” in patients with ischemic heart disease.

Received 5 October 2016. Accepted 6 December 2016.

Funding: This study was funded by “Angioline Interventional Devices”, 630090, 18 Inzhenernaya Street, Novosibirsk, Russian Federation.
Conflict of interest: The authors declare no conflict of interest.


A. A. Prokhorikhin
E.N. Meshalkin Siberian Federal Biomedical Research Center, Ministry of Health Care of Russian Federation, 630055, Novosibirsk, Russian Federation

Email:  a_prohorihin@meshalkin.ru 

V. V. Verin
Primorsky Regional Clinical Hospital No. 1, 690091, Vladivostok, Russian Federation

A. G. Osiev
Moscow Regional Research and Clinical Institute, 129110, Moscow, Russian Federation

V. I. Ganyukov
Research Institute for Complex Issues of Cardiovascular Diseases, 650002, Kemerovo, Russian Federation

A. V. Protopopov
Regional Clinical Hospital, 660022, Krasnoyarsk, Russian Federation

V. V. Dyomin
Orenburg Regional Clinical Hospital, 460018, Orenburg, Russian Federation

S. A. Abugov
Petrovsky Russian Research Centre of Surgery, Ministry of Health Care of Russian Federation, 119991, Moscow, Russian Federation

V. I. Baystrukov
E.N. Meshalkin Siberian Federal Biomedical Research Center, Ministry of Health Care of Russian Federation, 630055, Novosibirsk, Russian Federation

I. O. Grazhdankin
E.N. Meshalkin Siberian Federal Biomedical Research Center, Ministry of Health Care of Russian Federation, 630055, Novosibirsk, Russian Federation

D. N. Ponomaryov
E.N. Meshalkin Siberian Federal Biomedical Research Center, Ministry of Health Care of Russian Federation, 630055, Novosibirsk, Russian Federation

E. I. Kretov
E.N. Meshalkin Siberian Federal Biomedical Research Center, Ministry of Health Care of Russian Federation, 630055, Novosibirsk, Russian Federation

References


    1. Kinnaird T, Kwok CS, Narain A, Butler R, Ossei-Gerning N, Ludman P, Moat N, Anderson R, Mamas MA. Meta-Analysis of Percutaneous Coronary Intervention With Drug-Eluting Stent Versus Coronary Artery Bypass Grafting for Isolated Proximal Left Anterior Descending Coronary Disease. Am J Cardiol. 2016;118(8):1171-7. https://dx.doi.org/10.1016/j.amjcard.2016.07.030   
    2. Kuznetsov VA, Bessonov IS, Pushkarev GS, Musikhina NA, Gultyaeva EP, Zyrianov IP, Gorbatenko YeA, Sapozhnikov SS. Prospective registry of percutaneous coronary interventions: Tyumen Cardiology Center’s experience. Patologiya krovoobrashcheniya i kardiokhirurgiya = Circulation Pathology and Cardiac Surgery. 2015;19(3):80-6. (In Russ.)
    3. Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE. Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Coronary Restenosis. Circulation. 2004;109(5):634-40.
    4. Sukhanov SG, Orekhova YeN, Sharlaimov SA. Clinical-echocardiographic results of myocardial revascularization and mitral annuloplasty in patients with I-II degree ischemic mitral regurgitation. Patologiya krovoobrashcheniya i kardiokhirurgiya = Circulation Pathology and Cardiac Surgery. 2012;16(2):53-8. (In Russ.)
    5. Jensen LO, Thayssen P, Christiansen EH, Maeng M, Ravkilde J, Hansen KN, Hansen HS, Krusell L, Kaltoft A, Tilsted HH, Berencsi K, Junker A, Lassen JF; SORT OUT IV Investigators. Safety and Efficacy of Everolimus-Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV. J Am Coll Cardiol. 2016;67(7):51-62. http://dx.doi.org/10.1016/j.jacc.2015.11.051 
    6. Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas JS Jr, Popma JJ; ENDEAVOR IV Investigators. Late Safety, Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions 2-Year Follow-Up From the ENDEAVOR IV Trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2009;2(12):1208-18.
    7. Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y, Shiode N, Kimura T; NEXT Investigators. Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent. J Am Coll Cardiol. 2013;62(3):181-90. http://dx.doi.org/10.1016/j.jacc.2013.04.045 
    8. Bokeriya LA, Alekyan BG. Rentgenendovaskulyarnye diagnostika i lechenie zabolevaniy serdtsa i sosudov Rossiyskoy Federatsii – 2015. Moscow: A.N. Bakoulev Scientific Center for Cardiovascular Surgery; 2016. 22 p. (in Russ.)
    9. Beijk MA, Neumann FJ, Wiemer M, Grube E, Haase J, Thuesen L, Hamm C, Veldhof S, Dorange C, Serruys PW, Piek JJ. Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial). Eurointervention. 2007;3(2):206-12.
    10. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrié D, Thuesen L, Boone E, Miquel-Herbert K, Daemen J. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. Eurointervention. 2006;2(3):286-94.
    11. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents two-year clinical follow-up from the clinical evaluation of the Xience V Everolimus Eluting Coronary Stent System in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III Trial. Circulation. 2009;119(5):680-6. http://dx.doi.org/10.1161/CIRCULATIONAHA.108.803528 
    12. Costa M, Kereiakes D, Smith R, Wu K, Yu X, Cannon L, Wang J, Sudhir K. TCT-608 Two-Year Outcomes after Implantation of XIENCE PRIME and XIENCE PRIME Long Lesion Stents in Patients with Coronary Artery Disease: Results of the SPIRIT PRIME Multicenter Pivotal Clinical Trial. J Am Coll Cardiol. 2012;60(17 Suppl):B176-7. http://dx.doi.org/10.1016/j.jacc.2012.08.645  
    13. Osiev AG, Redkin DA, Marchenko AV, Grankin DS, Vereschaguin MA, Biriukov AV, Kretov EI, Zubarev DD, Krestianinov OV, Ibraguimov RU, Baystrukov VI. Evaluation of the effectiveness of endovascular treatment of ischemic heart disease with stenotic left main coronary artery. International Journal of Interventional Cardioangiology. 2009.(19):52. (in Russ.)

Prokhorikhin A. A., Verin V. V., Osiev A. G., Ganyukov V. I., Protopopov A. V., Dyomin V. V., Abugov S. A., Baystrukov V. I., Grazhdankin I. O., Ponomaryov D. N., Kretov E. I. Prospective rAndomized, single-blind, mulTicenter control clinical study of sirolimus-eluting coRonary stent “Calypso” vs everolimus-elutIng cOronary stenT “Xience Prime”: design and rationale for “PATRIOT” trial. Patologiya krovoobrashcheniya i kardiokhirurgiya = Circulation Pathology and Cardiac Surgery. 2016;20(4):96-101. (In Russ.). http://dx.doi.org/10.21688/1681-3472-2016-4-96-101


DOI: http://dx.doi.org/10.21688/1681-3472-2016-4-96-101

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.